Abschluss eines nicht exklusiven Rabattvertrages nach§ 130a Abs. 8 SGB V zu Arzneimitteln mit dem Wirkstoff Sorafenib (ATC-Code: L01EX02) innerhalb des Zeitraumes vom 01.12.2026 bis zum 30.11.2028 mit jederzeitiger Möglichkeit des Vertragsabschlusses während der Laufzeit („open-house-Modell“).

TENDER DESCRIPTION

For the active ingredient Sorafenib (ATC code: L01EX02), AOK Niedersachsen offers it. For the period until the entry into force of exclusive agreements as a result of a formal procurement procedure in accordance with the provisions of Part 4 of the GWB, all interested pharmaceutical companies are offered discount agreements by AOK Niedersachsen without a selection decision. The contract awards are made within the framework of an “open-house model” and serve as a bridge between the start of generic competition (expiry of the patent) and the award of exclusive agreements. The agreements offered are non-exclusive; agreements with all market participants (pharmaceutical companies) are desired by AOK Niedersachsen. In the open-house model, uniform conditions apply to all participants. Contract content, terms and access procedures are uniform—individual negotiations are generally not conducted. Contract terms are a maximum of twenty-four months; the earliest contract start date is 01.12.2026. All contracts end no later than 30.11.2028, irrespective of the date on which the respective contract is concluded. Admission/contract conclusion can be made within the twenty-four-month period,…

TENDER BRIEF

TENDER DOCUMENTS